IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, has signed a loan financing agreement with the European Investment Bank (EIB), amounting to €10 million. The financing agreement with the EIB will provide non-dilutive financing for the company to accelerate product development and clinical data generation for its IRRAflow platform in the European Union. The financing from the EIB falls under the new venture debt programme of the European Guarantee Fund, set up in 2020 to assist European companies that have come under strain due to the COVID-19 pandemic.
The European Investment Bank (EIB) has signed a loan agreement of up to SEK 311 million with Renewcell from Sweden. The loan was extended under “InnovFin – EU Finance for Innovators”, with the financial backing of the European Union under Horizon 2020, the EU’s programme for research and innovation.
The European Investment Bank (EIB) has signed a €50 million (SEK 505 million) loan agreement with the European Spallation Source (ESS) in Lund, Sweden. The credit facility was extended under the “InnovFin – EU Finance for Innovators” programme, with the financial backing of the European Union under Horizon 2020, the EU’s programme for research and innovation. This loan follows an existing credit facility started in 2016, for a total exposure of €200million. The construction of the ESS is progressing despite the ongoing COVID-19 pandemic, with about three quarters of the project complete at the end of 2020.